Europe’s IT, Business Services Market Boosted by AI-Driven Cloud Demand in Q2: ISG Index™
14.7.2025 10:00:00 CEST | Business Wire | Press Release
Strong interest in AI continued to drive cloud services growth in Europe during the second quarter, even as demand for managed services slowed under the weight of macro uncertainty, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.
The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) advanced 14 percent, to US $9.0 billion. Although up double digits year on year, the combined market declined 1.2 percent sequentially from the first quarter, as economic and geopolitical concerns limited discretionary spending on managed services.
“Europe continues to embrace the cloud for AI adoption and cost efficiency,” said Steve Hall, president, ISG EMEA and the firm’s chief AI officer. “Given the region’s macroeconomic and geopolitical instability, there has been a lot of discussion around digital sovereignty in Europe. We view sovereign clouds as a potential growth segment for the industry going forward.”
Second-Quarter Results by Segment
ACV for the as-a-service (XaaS) segment soared 34 percent year on year, to a record US $5.1 billion, and was up 7 percent sequentially from the first quarter. It was the fifth straight quarter XaaS has grown by double digits, averaging 31 percent in that span, although the Q2 growth rate moderated slightly (down 170 basis points) from Q1.
Within this segment, infrastructure-as-a-service (IaaS) climbed 43 percent year on year, to a record US $3.9 billion, while growing 13 percent from the first quarter. Software-as-a-service (SaaS) grew 12 percent versus the prior year, to US $1.2 billion, although it was down 7 percent sequentially.
Managed services ACV in the second quarter dipped 4 percent, to US $3.9 billion, and was down 11 percent sequentially from the first quarter. A total of 240 managed services contracts were awarded in the quarter, down 20 percent from the prior year and down 14 percent from Q1. Among them were three mega deals (ACV of US $100 million or more), compared with four signed in the second quarter last year. Still, the total ACV of the mega deals was up 9 percent year on year, as companies continued to emphasize larger deals aimed cost optimization. The volume of smaller deals under US $10 million declined 31 percent year on year, as enterprises limited discretionary projects.
Within managed services, IT outsourcing (ITO) slumped 21 percent, to US $2.6 billion, with data center services the only growth area. Business process outsourcing (BPO), meanwhile, rose 23 percent, to US $667 million, led by growth in customer engagement, facilities management and finance and accounting services.
By industry, managed services ACV was higher in travel, transportation and leisure (up 90 percent), business services (up 74 percent) and retail (up 10 percent), while the region’s three largest sectors showed mixed results. Energy and manufacturing were up 4 percent and 3 percent, respectively, but banking, financial services and insurance (BFSI), Europe’s largest industry for sourcing, fell 8 percent.
ACV in the engineering, research and development (ER&D) segment, meanwhile, reached US $953 million, up 193 percent year on year and up 64 percent from the first quarter, as companies invested in digital integration and innovation.
Geographic Performance
EMEA's largest managed services market, the DACH region, grew 11 percent year on year, to US $1.0 billion, while France rose to the number two spot for ACV, at US $817 million, up 142 percent from the prior year. The UK, traditionally Europe’s largest sourcing market, dropped to third place, at US $770 million, down 41 percent from the prior year. The Nordics, coming in fourth, climbed 72 percent, to US $471 million of ACV.
First-Half Results
For the first half, combined market ACV rose 19 percent, to US $18.2 billion. Managed services, at US $8.3 billion, was up 3.4 percent, while XaaS, at US $9.9 billion, rose 35 percent versus the same period last year. A total of 518 managed services contracts were awarded in the half, down 11 percent from last year, including six mega-deals, even with the prior year. The total ACV of the mega-deals, however, advanced 10 percent year on year.
Within managed services, ITO was essentially flat (up 0.2 percent), at US $6.1 billion, while BPO declined 16 percent, to US $1.2 billion. On the cloud side, the IaaS market grew 41 percent, to US $7.4 billion, while the SaaS market rose 20 percent, to US $2.5 billion.
ER&D services more than doubled from the prior year, to $953 million of ACV.
2025 Global Forecast
For the full year, ISG is maintaining its forecast of 1.3 percent revenue growth for managed services, reflecting a stabilizing tariff environment but also continued weakness in discretionary spending. At the same time, ISG is raising its previous growth forecast for cloud-based XaaS by 300 basis points, to 21 percent, based on continuing strong demand for AI-driven transformation.
Hall commented: “In terms of our macro outlook, it has improved over the last 90 days, yet business uncertainty remains high. That said, AI has emerged as the dominant theme, overcoming many of these concerns to drive the overall market forward.”
About the ISG Index™
The ISG Index™ is recognized as the authoritative source for marketplace intelligence on the global technology and business services industry. For 91 consecutive quarters, it has detailed the latest industry data and trends for financial analysts, enterprise buyers, software and service providers, law firms, universities and the media.
The 2Q25 Global ISG Index results were presented during a webcast on July 10. To view a replay of the webcast and download presentation slides, visit this webpage.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714957081/en/
Contacts
Press Contacts:
Philipp Jaensch, ISG
+49 151 730 365 76
philipp.jaensch@isg-one.com
Will Thoretz, ISG
+1 203 517 3119
will.thoretz@isg-one.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom